Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 8/20 | 0.75 |
| ▸ | THRA | P10827 | 6/20 | 0.60 |
| ▸ | THRB | P10828 | 6/20 | 0.60 |
| ▸ | RARB | P10826 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | RARA | P10276 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14749470 | 1.00 | BCHE (0.75) | BCHETHRATHRBRARBMEN1 | |
| SCHEMBL18133142 | 1.00 | BCHE (0.75) | BCHETHRATHRBRARBMEN1 | |
| SCHEMBL12902930 | 0.95 | BCHE (0.70) | BCHETHRATHRBRARBMEN1 | |
| SCHEMBL19556702 | 0.95 | BCHE (0.70) | BCHETHRATHRBRARBMEN1 | |
| SCHEMBL12902931 | 0.94 | BCHE (0.68) | BCHETHRATHRBRARBMEN1 | |
| SCHEMBL16436179 | 0.93 | BCHE (0.67) | BCHETHRATHRBRARBMAPT | |
| SCHEMBL14264266 | 0.90 | BCHE (0.63) | BCHETHRATHRBRARB | |
| SCHEMBL10306615 | 0.90 | BCHE (0.63) | BCHETHRATHRBRARB | |
| SCHEMBL21704943 | 0.90 | BCHE (0.63) | BCHETHRATHRBRARB | |
| SCHEMBL15764102 | 0.90 | BCHE (0.63) | BCHETHRATHRBRARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2753675-B1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2018-05-02 | — | — | EP | disclosed |
| US-20160115388-A1 | MESOGENIC COMPOUND, LIQUID-CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2016-04-28 | — | — | US | disclosed |
| US-20160115388-A1 | MESOGENIC COMPOUND, LIQUID-CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2016-04-28 | — | — | US | disclosed |
| EP-2708587-B1 | Liquid crystal medium and liquid crystal display | MERCK PATENT GMBH (DE) | 2015-07-15 | — | — | EP | disclosed |
| WO-2015101405-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2015-07-09 | — | — | WO | disclosed |
| EP-2568032-B1 | Liquid crystal medium and liquid crystal display | MERCK PATENT GMBH (DE) | 2014-11-26 | — | — | EP | disclosed |
| US-20140158934-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2014-06-12 | — | — | US | disclosed |
| US-20140158934-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2014-06-12 | — | — | US | disclosed |
| EP-2708587-A1 | Liquid crystal medium and liquid crystal display | Merck Patent GmbH (DE) | 2014-03-19 | — | — | EP | disclosed |
| EP-2568032-A2 | Liquid crystal medium and liquid crystal display | Merck Patent GmbH (DE) | 2013-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115388-A1 | MESOGENIC COMPOUND, LIQUID-CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | BMP2, IK, EML4 | BCHE 3124/4885THRA 4397/4885THRB 3904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.